share_log

Retail Investors Invested in SMO ClinPlus CO.,LTD. (SZSE:301257) Copped the Brunt of Last Week's CN¥379m Market Cap Decline

先週のCN¥379mの市場時価総額の減少で、リテール投資家はSMO ClinPlus株式会社(SZSE:301257)に投資し、支払いを受けました。

Simply Wall St ·  03/27 18:10

Key Insights

  • The considerable ownership by retail investors in SMO ClinPlusLTD indicates that they collectively have a greater say in management and business strategy
  • A total of 6 investors have a majority stake in the company with 51% ownership
  • Insiders own 13% of SMO ClinPlusLTD

To get a sense of who is truly in control of SMO ClinPlus CO.,LTD. (SZSE:301257), it is important to understand the ownership structure of the business. With 28% stake, retail investors possess the maximum shares in the company. In other words, the group stands to gain the most (or lose the most) from their investment into the company.

As market cap fell to CN¥2.9b last week, retail investors would have faced the highest losses than any other shareholder groups of the company.

Let's take a closer look to see what the different types of shareholders can tell us about SMO ClinPlusLTD.

ownership-breakdown
SZSE:301257 Ownership Breakdown March 27th 2024

What Does The Institutional Ownership Tell Us About SMO ClinPlusLTD?

Institutional investors commonly compare their own returns to the returns of a commonly followed index. So they generally do consider buying larger companies that are included in the relevant benchmark index.

We can see that SMO ClinPlusLTD does have institutional investors; and they hold a good portion of the company's stock. This implies the analysts working for those institutions have looked at the stock and they like it. But just like anyone else, they could be wrong. It is not uncommon to see a big share price drop if two large institutional investors try to sell out of a stock at the same time. So it is worth checking the past earnings trajectory of SMO ClinPlusLTD, (below). Of course, keep in mind that there are other factors to consider, too.

earnings-and-revenue-growth
SZSE:301257 Earnings and Revenue Growth March 27th 2024

We note that hedge funds don't have a meaningful investment in SMO ClinPlusLTD. Shanghai Xibao Investment Management Co., Ltd. is currently the company's largest shareholder with 19% of shares outstanding. With 8.0% and 7.9% of the shares outstanding respectively, Shihezi Ruixin Equity Investment Partnership Enterprise (Limited Partnership) and Shanghai Guanyou Investment and Development Co., Ltd. are the second and third largest shareholders.

We did some more digging and found that 6 of the top shareholders account for roughly 51% of the register, implying that along with larger shareholders, there are a few smaller shareholders, thereby balancing out each others interests somewhat.

While studying institutional ownership for a company can add value to your research, it is also a good practice to research analyst recommendations to get a deeper understand of a stock's expected performance. As far as we can tell there isn't analyst coverage of the company, so it is probably flying under the radar.

Insider Ownership Of SMO ClinPlusLTD

The definition of company insiders can be subjective and does vary between jurisdictions. Our data reflects individual insiders, capturing board members at the very least. Management ultimately answers to the board. However, it is not uncommon for managers to be executive board members, especially if they are a founder or the CEO.

Insider ownership is positive when it signals leadership are thinking like the true owners of the company. However, high insider ownership can also give immense power to a small group within the company. This can be negative in some circumstances.

Our information suggests that insiders maintain a significant holding in SMO ClinPlus CO.,LTD.. Insiders own CN¥392m worth of shares in the CN¥2.9b company. We would say this shows alignment with shareholders, but it is worth noting that the company is still quite small; some insiders may have founded the business. You can click here to see if those insiders have been buying or selling.

General Public Ownership

With a 28% ownership, the general public, mostly comprising of individual investors, have some degree of sway over SMO ClinPlusLTD. While this group can't necessarily call the shots, it can certainly have a real influence on how the company is run.

Private Equity Ownership

With an ownership of 26%, private equity firms are in a position to play a role in shaping corporate strategy with a focus on value creation. Some investors might be encouraged by this, since private equity are sometimes able to encourage strategies that help the market see the value in the company. Alternatively, those holders might be exiting the investment after taking it public.

Private Company Ownership

Our data indicates that Private Companies hold 8.0%, of the company's shares. It might be worth looking deeper into this. If related parties, such as insiders, have an interest in one of these private companies, that should be disclosed in the annual report. Private companies may also have a strategic interest in the company.

Next Steps:

While it is well worth considering the different groups that own a company, there are other factors that are even more important.

Many find it useful to take an in depth look at how a company has performed in the past. You can access this detailed graph of past earnings, revenue and cash flow.

If you would prefer check out another company -- one with potentially superior financials -- then do not miss this free list of interesting companies, backed by strong financial data.

NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

これらの内容は、情報提供及び投資家教育のためのものであり、いかなる個別株や投資方法を推奨するものではありません。 更に詳しい情報
    コメントする